Healthcare
Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants
Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499
About this update from Q32 Bio Inc.
WALTHAM, Mass., July 14, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB), ("Q32 Bio") a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases, today announced the pricing of an underwritten public offering of 6,027,399 shares of its common stock at a public offering price of $18.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 4,931,506 shares of its common stock at a public offering price of $18.2499 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each pre-funded warrant. In addition, Q32 Bio has granted the underwriters a 30-day option to purchase up to an additional 1,643,835 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Q32 Bio from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Q32 Bio, are expected to be approximately $200 million, assuming no exercise of the underwriters' option to purchase additional shares and excluding any exercise of the pre-funded warrants. The offering is expected to close on or about July 16, 2026, subject to the satisfaction of customary closing conditions. All shares and pre-funded warrants in the offering are being sold by Q32 Bio. Morgan Stanley, Jefferies and Cantor are acting as joint book-running managers for the offering. Oppenheimer & Co. is also acting as a book-running manager for the offering, and H.C. Wainwright & Co. is acting as lead manager for the offering. Q32 Bio intends to use the net proceeds of the offering for working capital purposes, including expenses related to research, clinical development and commercialization efforts including for supporting the advancement of bempikibart into future clinical trials. The securities described above are being offered by Q32 Bio pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-297027) that was filed with the Securities and Exchange Commission (the "SEC") on June 25, 2026 and declared effective on July 13, 2026. This offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the offering have been filed with the SEC, and a final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and, when available, copies of the final prospectus supplement, and the accompanying prospectus relating to the offering may be obtained by visiting the SEC's website at www.sec.gov or by contacting Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at (866) 718-1649 or by email at [email protected]; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at [email protected]; Cantor Fitzgerald & Co., Attention: Equity Capital Markets, 110 E. 59th Street, 6th Floor, New York, New York 10022, or by email at [email protected]; or Oppenheimer & Co. Inc. Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at [email protected].